Due to the exceptionally high PSMA expression in metastatic castration-resistant prostate cancer, a theranostics treatment based on Lutetium-177 (177Lu) bound to PSMA-617 used to deliver local radiation to disease was investigated in the prospective LuPSMA clinical trial (ID: ANZCTR12615000912583) (12). The gene discussed is FOLH1; the disease is prostate carcinoma.